Artelo Biosciences notified by Nasdaq of equity deficiency; $652K vs $2.5M minimum

ARTELO BIOSCIENCES, INC.

As of March 31, 2025, stockholders' equity was $652,000, below the $2.5M minimum required by Nasdaq Rule 5550(b)(1).
Company has 45 days (until July 7, 2025) to submit a compliance plan to Nasdaq.
If plan accepted, Nasdaq may grant up to 180 days (until Nov 18, 2025) to evidence compliance.
No immediate impact on listing; common stock continues trading on Nasdaq pending review.
Company evaluating options; no assurance that compliance plan will be accepted or delisting avoided.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.